Publications by authors named "Ruo-Qi Xie"
Article Synopsis
- Cisplatin is a common chemotherapy used for nasopharyngeal carcinoma (NPC), but some patients can't use it due to eligibility issues or past severe reactions.
- A phase 2 trial tested the combination of gemcitabine and toripalimab on patients who couldn't take cisplatin, showing good results in terms of safety and effectiveness.
- Out of 21 enrolled patients, the therapy had a 61.9% objective response rate and a perfect disease control rate, with manageable side effects like headaches and nausea.
Article Synopsis
- Locoregional radiotherapy, combined with chemotherapy, has improved survival rates for patients with de novo metastatic nasopharyngeal carcinoma (mNPC), but only 54% achieve a response after treatment.
- A phase II study investigated the effect of adding a PD-1 inhibitor to standard treatment, finding an objective response rate of 81.8% among 22 enrolled patients after 3 months.
- Despite the promising results, 68.2% of patients experienced severe side effects, and higher levels of Epstein-Barr virus DNA were linked to poorer progression-free survival.
Background: Reirradiation in standard fractionation for locally advanced recurrent nasopharyngeal carcinoma after a previous course of high-dose radiotherapy is often associated with substantial late toxicity, negating its overall benefit. We therefore aimed to investigate the efficacy and safety of hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy.
Methods: This multicentre, randomised, open-label, phase 3 trial was done in three centres in Guangzhou, China.
Purpose: Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC).
Methods: This single-arm, Simon two-stage study enrolled patients with recurrent/metastatic NPC who were refractory to at least first-line systemic therapy and treatment-naive to immune checkpoint inhibitors.
Background: Studies of local therapy (LT) to metastatic foci from nasopharyngeal carcinoma (NPC) are inconsistent and controversial. Here, we aimed to explore the survival benefit of LT directed at metastatic foci from NPC.
Methods: A retrospective analysis was conducted in NPC patients with liver, lung, and/or bone metastases.